The global bronchodilators market size reached USD 39.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 57.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.15% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 39.3 Billion |
Market Forecast in 2033
|
USD 57.7 Billion |
Market Growth Rate 2025-2033 | 4.15% |
Bronchodilators are medications used to treat patients suffering from long-term conditions of narrow and inflamed airways, such as asthma, emphysema, and chronic obstructive pulmonary disease (COPD). They help relieve associated symptoms by relaxing the muscles around the airways or bronchi, clearing mucus from the lungs, and making breathing easier. They are available in the form of tablets, liquid, nebulizer solutions, and metered-dose and dry powder inhalers. Nowadays, bronchodilators are also utilized to enhance the effect of inhaled corticosteroids, which act as a primary treatment to reduce inflammation and prevent flare-ups in asthma.
A significantly rising number of patients with acute respiratory infections due to coronavirus disease (COVID-19) represents one of the key factors influencing the need for bronchodilators across the globe. Apart from this, increasing levels of air pollution, the rising number of smokers, and the growing prevalence of infectious diseases around the world are contributing to the risk of developing lung conditions. This is acting as another growth-inducing factor of the market. In addition, lung function declines gradually with age, which can make breathing slightly difficult. This, along with the increasing geriatric population and a considerable rise in consumer spending capacities, is driving the market. Other factors, such as improving healthcare infrastructure and diagnostic modalities and rising shift towards non-invasive procedures, are also propelling the market growth. Furthermore, several new classes of bronchodilators that can help overcome the limitations of existing products are in the preclinical phase stage. In confluence with this, health agencies of numerous countries are supporting research and development (R&D) activities for bronchodilators, which is anticipated to create a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global bronchodilators market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on indication, drug type and route of administration.
Breakup by Indication:
Breakup by Drug Type:
Breakup by Route of Administration:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. and Vectura Group plc.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Indication, Drug Type, Route of Administration, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. and Vectura Group plc |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global bronchodilators market was valued at USD 39.3 Billion in 2024.
We expect the global bronchodilators market to exhibit a CAGR of 4.15% during 2025-2033.
The rising pollution levels, along with the increasing prevalence of numerous chronic respiratory diseases, such as asthma, Chronic Obstructive Pulmonary Disease (COPD), allergic reactions, etc., are primarily driving the global bronchodilators market.
The sudden outbreak of the COVID-19 pandemic has led to the growing adoption of bronchodilators, owing to the growing number of the coronavirus infected patients with acute respiratory conditions.
Based on the indication, the global bronchodilators market can be segmented into asthma, Chronic Obstructive Pulmonary Disease (COPD), and others. Currently, asthma holds the majority of the total market share.
Based on the drug type, the global bronchodilators market has been divided into sympathomimetics, anticholinergics, phosphodiesterase inhibitor, and combination drugs. Among these, anticholinergics currently exhibit a clear dominance in the market.
Based on the route of administration, the global bronchodilators market can be categorized into oral, injection, and inhaler. Currently, inhaler accounts for the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global bronchodilators market include Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and Vectura Group plc.